Please use this identifier to cite or link to this item:
Title: Albendazole therapy for eosinophilic meningitis caused by Angiostrongylus cantonensis
Authors: Suthipun Jitpimolmard
Kittisak Sawanyawisuth
Nimit Morakote
Athasit Vejjajiva
Montien Puntumetakul
Kanokwan Sanchaisuriya
Wongwiwat Tassaneeyakul
Wichittra Tassaneeyakul
Narumanas Korwanich
Keywords: Agricultural and Biological Sciences
Immunology and Microbiology
Issue Date: 1-May-2007
Abstract: Eosinophilic meningitis in humans is commonly caused by the nematode Angiostrongylus cantonensis. A severe headache is the most common presenting symptom. A prospective, randomized, double-blind, placebo, controlled study was conducted to determine if albendazole was efficacious in relieving such headaches. Seventy-one patients (36 and 35 in the treatment and control groups) were enrolled in the study. Five patients (two and three in the treatment and control groups) were excluded from the study because of being lost to follow-up, and the clinical data were incomplete. Therefore, 34 and 32 patients in the treatment and control groups were studied, respectively. Albendazole was administered at 15 mg/kg/day or identical placebo for 2 weeks. The number of patients with persistent headaches after 2 weeks was 7 and 13 in the albendazole and placebo groups (p=0.08), respectively. The mean duration of a headache was 8.9 and 16.2 days in the albendazole and placebo groups, respectively (p=0.05). No serious drug events were observed. A 2-week course of albendazole appeared to reduce the duration of headache in eosinophilic meningitis. © 2006 Springer-Verlag.
ISSN: 09320113
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.